| 초록 |
A number of clinically used drugs can cause side effects on the functions of the heart, such as torsades de pointes (TdP), and lead to withdraw from the pharmaceutical market in clinical use. Therefore, the nonclinical cardiotoxicity testing has become an important part of the regulatory procedure, such as electrocardiogram (ECG), action potential and ion currents. Despite all the efforts to establish and to validate preclinical models, none of the preclinical in vitro and in vivo methods have been proven to be fully predictive for QT prolongation and for torsadogenic potential because of interspecies differences. In addition to the differences between species, ethical concerns about the use of laboratory animals and investing a lot of time and money act as obstacles to the development of new drugs, a new paradigm of nonclinical cardiotoxicity testing is required. Therefore, I would like to introduce the development of alternative toxicity models in our laboratory. |
